These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31930450)

  • 1. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users.
    Stern AD; Chen JL; Ouellet M; Trusheim MR; El-Kilani Z; Jessup A; Berndt ER
    Health Aff (Millwood); 2021 Jun; 40(6):989-999. PubMed ID: 34097520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
    Barszczewska O; Piechota A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
    Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 10. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
    Niazi SK
    J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
    Chen HH; Yemeke T; Ozawa S
    PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
    Feng K; Russo M; Maini L; Kesselheim AS; Rome BN
    JAMA Health Forum; 2024 Mar; 5(3):e235429. PubMed ID: 38551589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.
    Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK
    J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.
    Wu Q; Wang Z; Fu Y; Luo R; Sun J
    Glob Health Res Policy; 2024 Oct; 9(1):42. PubMed ID: 39367503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected US savings from biosimilars, 2021-2025.
    Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
    Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
    Kim SC; Choi NK; Lee J; Kwon KE; Eddings W; Sung YK; Ji Song H; Kesselheim AS; Solomon DH
    Arthritis Rheumatol; 2016 May; 68(5):1076-9. PubMed ID: 26662931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
    Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
    Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.